Psychiatric disorders Archives

In Depth 12 Sep 2024

New treatments being developed for schizophrenia

Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.

September 12, 2024

Psychedelic therapy market: FDA rejects Lykos' MDMA treatment

News and Trends 6 Sep 2024

Psychedelic therapies under scrutiny: What’s next after Lykos’ MDMA rejection?

Delve into the psychedelic-assisted therapy market and investors’ sentiment after the FDA’s decision about Lykos’ therapy.

September 6, 2024 - 8 minutesmins - By Jules Adam

Best in Biotech 25 Jan 2024

Eight mental health biotech companies trying to make a difference to people’s lives

Take a closer look at eight mental health companies developing therapies that could make a different to people with mental illnesses.

January 25, 2024 - 11 minutesmins - By Willow Shah-Neville

News and Trends 22 Sep 2023

U.S. approval for psychedelic drug MDMA nears after success in clinic

The psychedelic drug MDMA edges closer towards FDA approval for the treatment of post-traumatic stress disorder (PTSD) in the U.S., after promising results of a trial were published. This comes after Australia became the first country to allow doctors to prescribe the drug to those struggling with mental health disorders like PTSD and depression. Recognizing […]

September 22, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 24 Oct 2022

Beckley Psytech acquires Eleusis Therapeutics

Beckley Psytech Limited has entered into a definitive agreement to acquire clinical-stage life science company Eleusis Therapeutics Limited in an all equity transaction. Under the terms of the agreement, which has been approved by shareholders, Beckley Psytech has acquired 100% of Eleusis, receiving full developmental and commercial rights for the company’s assets, which will further […]

October 24, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Spinoff Biohaven launches with $258M and “incredible pipeline”

Biohaven Ltd. launched today as a new publicly traded company focused on delivering innovative life-changing treatments for neurological and neuropsychiatric diseases, including rare disorders. As of today, Biohaven has officially begun operating as a separate independent entity as part of the acquisition agreement with Pfizer in May 2022. The company, led by Vlad Coric as […]

October 4, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 25 Jul 2022

Drug for acute treatment of social anxiety disorder did not meet primary endpoint

A nasal spray to treat anxiety did not meet its primary endpoint and was not significantly better than the placebo given during a phase 3 clinical trial. Vistagen Therapeutics Inc’s drug, PH94B, was designed to treat people living with anxiety, depression and other central nervous system (CNS) disorders announced the topline results on Friday (July […]

July 25, 2022 - 4 minutesmins - By Liza Laws

Best in Biotech 22 Jun 2022

The top psychedelic drug developers leading the market

Psychedelic drugs have the potential to become an effective treatment for crippling mental health conditions such as depression. Here are five of the top drug developers leading their particular niches in the emerging field of psychedelic medicines. For decades, research into the therapeutic properties of psychedelic drugs was almost snuffed out as recreational use of […]

June 22, 2022 - 7 minutesmins - By Jonathan Smith

tourette syndrome treatment noema pharma

News and Trends 7 Dec 2020

Swiss Startup Tackles Tourette’s Syndrome Despite Recent Failures

In spite of recent failures of clinical trials from others in the field, Swiss company Noema Pharma is gearing up to develop better treatments for the neurological condition Tourette’s syndrome. Noema Pharma will use a recent €49M Series A round to bankroll the phase I development of a candidate for Tourette’s syndrome along with the […]

December 7, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 8 May 2019

Schizophrenia Treatments Could be Tested and Personalized Using Patients’ Blood

Scientists at the University of Cambridge have developed a way to screen treatments for schizophrenia on single cells from a patient’s blood sample, which could speed up drug discovery and help to personalize treatments for people with the condition. Around 21 million people worldwide suffer from schizophrenia, and this is likely to get worse with […]

May 8, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 9 Oct 2018

Slow-Release Drug Biotech IPO Raises €30M

The French biotech MedinCell, an injectable slow-release drug specialist, has received a shot of success as its IPO raises €30M in the Euronext stock exchange in Paris. MedinCell is hoping to improve patient compliance with medication regimes by injecting them with a drug-infused gel. Patient compliance with taking medication can be as low as 30% […]

October 9, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 19 Dec 2017

Schizophrenia and Drug Delivery Biotechs Sign a Major Pharma Partner

Santa Claus is not the only busy one in the weeks leading up to Christmas this year, with Boehringer Ingelheim signing collaborations with Autifony and Evox Therapeutics. In the last couple of days, Boehringer Ingelheim has agreed to collaborate with two exciting British biotechs. On Monday, a deal worth up to €627.5M was agreed with CNS disorders specialist, […]

December 19, 2017 - 2 minutesmins - By Alex Dale

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Psychiatric disorders

New treatments being developed for schizophrenia

Psychedelic therapies under scrutiny: What’s next after Lykos’ MDMA rejection?

Eight mental health biotech companies trying to make a difference to people’s lives

U.S. approval for psychedelic drug MDMA nears after success in clinic

Beckley Psytech acquires Eleusis Therapeutics

Spinoff Biohaven launches with $258M and “incredible pipeline”

Drug for acute treatment of social anxiety disorder did not meet primary endpoint

The top psychedelic drug developers leading the market

Swiss Startup Tackles Tourette’s Syndrome Despite Recent Failures

Schizophrenia Treatments Could be Tested and Personalized Using Patients’ Blood

Slow-Release Drug Biotech IPO Raises €30M

Schizophrenia and Drug Delivery Biotechs Sign a Major Pharma Partner

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!